ALKERMES | ALKS - Interest Income


ALKERMES reported $8.54M in Interest Income for its fiscal quarter ending in March of 2026.





Interest Income Change Date
AbbVie USD 72M 13M Mar/2026
Acadia Pharmaceuticals USD 8.06M 277K Mar/2026
ALKERMES USD 8.54M 3.59M Mar/2026
Biogen USD 37.9M 700K Mar/2026
BioMarin Pharmaceutical USD 22.56M 3.35M Mar/2026
Eli Lilly USD 65M 25M Sep/2025
Gilead Sciences USD 95M 0 Mar/2026
Heron Therapeutics USD 433K 277K Dec/2021
Ionis Pharmaceuticals USD -0.66 0.29 Dec/2024
J&J USD 2.27 0.13 Jun/2026
Merck USD 35M 34M Mar/2026
Nektar Therapeutics USD -0.18 0.07 Sep/2024
Otsuka Holdings JPY 10.49B 396M Jun/2024
Pfizer USD -0.04 115M Jun/2026
Regeneron Pharmaceuticals USD 183.3M 200K Jun/2026
Vertex Pharmaceuticals USD 120.6M 5.8M Jun/2026